[HTML][HTML] Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population
RB Hansen, JF Simard, M Faurschou… - Journal of …, 2021 - Elsevier
The objective of this study was to assess the cumulative prevalence of pre-existing comorbidities
among patients diagnosed with systemic lupus erythematosus (SLE) in Denmark. The …
among patients diagnosed with systemic lupus erythematosus (SLE) in Denmark. The …
Risk of End‐Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort Study
RB Hansen, T Falasinnu, M Faurschou… - Arthritis care & …, 2023 - Wiley Online Library
Objective The risk of end‐stage renal disease (ESRD) is increased in patients with systemic
lupus erythematosus (SLE). This study was undertaken to determine whether diabetes …
lupus erythematosus (SLE). This study was undertaken to determine whether diabetes …
Novel treatments with small molecules in psoriatic arthritis
RB Hansen, A Kavanaugh - Current rheumatology reports, 2014 - Springer
Current treatment options for patients with active psoriatic arthritis (PsA) include synthetic
disease-modifying antirheumatic drugs and biologic agents. Propelled by increased …
disease-modifying antirheumatic drugs and biologic agents. Propelled by increased …
Clinical and serological associations with the development of incident proteinuria in Danish patients with systemic lupus erythematosus
N Tanha, RB Hansen, CT Nielsen… - The Journal of …, 2018 - jrheum.org
Objective. In a longitudinal cohort study, we investigated whether clinical and serological
manifestations at the time of classification of systemic lupus erythematosus (SLE) were …
manifestations at the time of classification of systemic lupus erythematosus (SLE) were …
How do women with lupus manage fatigue? A focus group study
…, KS Hougaard, A Berggreen, G Bukh, RB Hansen… - Clinical …, 2016 - Springer
Objective Half of patients with systemic lupus erythematosus (SLE) consider fatigue to be the
most disabling disease symptom. To develop and promote strategies to prevent and control …
most disabling disease symptom. To develop and promote strategies to prevent and control …
Secukinumab for the treatment of psoriatic arthritis
R Baronaite Hansen, A Kavanaugh - Expert Review of Clinical …, 2016 - Taylor & Francis
Introduction: Secukinumab (Cosentyx) is an interleukin-17A (IL-17A) inhibitor administered
subcutaneously. Through 2016, it had received approval in a number of countries, including …
subcutaneously. Through 2016, it had received approval in a number of countries, including …
Certolizumab pegol for the treatment of psoriatic arthritis.
RB Hansen, A Kavanaugh - Expert Review of Clinical Immunology, 2015 - europepmc.org
Certolizumab pegol (CZP) is a TNF-α inhibitor approved for the treatment of psoriatic
arthritis in 38 countries, including many European countries and the USA. It is a pegylated …
arthritis in 38 countries, including many European countries and the USA. It is a pegylated …
[HTML][HTML] A comparison of anti-nuclear antibody quantification using automated enzyme immunoassays and immunofluorescence assays
R Baronaite, M Engelhart, T Mørk Hansen… - Autoimmune …, 2014 - hindawi.com
Anti-nuclear antibodies (ANA) have traditionally been evaluated using indirect fluorescence
assays (IFA) with HEp-2 cells. Quantitative immunoassays (EIA) have replaced the use of …
assays (IFA) with HEp-2 cells. Quantitative immunoassays (EIA) have replaced the use of …
Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of followup
RB Hansen, S Jacobsen - The Journal of Rheumatology, 2014 - jrheum.org
Objective. Infections and thromboses are known complications of systemic lupus erythematosus
(SLE). We investigated if infectious episodes in patients with SLE were followed by an …
(SLE). We investigated if infectious episodes in patients with SLE were followed by an …
Certolizumab pegol for the treatment of psoriatic arthritis
R Baronaite Hansen, A Kavanaugh - Expert Review of Clinical …, 2015 - Taylor & Francis
Certolizumab pegol (CZP) is a TNF-α inhibitor approved for the treatment of psoriatic
arthritis in 38 countries, including many European countries and the USA. It is a pegylated …
arthritis in 38 countries, including many European countries and the USA. It is a pegylated …